<DOC>
	<DOC>NCT00701558</DOC>
	<brief_summary>This single arm study will assess the efficacy and safety of erlotinib + gemcitabine in chemotherapy-naive participants with unresectable, advanced and/or metastatic non-small cell lung cancer. Participants will receive erlotinib 150 mg orally (po) daily, in combination with gemcitabine 1000 mg/m^2 intravenously (iv) weekly for 3 weeks of each 4 week cycle. The anticipated time on study treatment is until disease progression, and the target sample size is &lt;100 individuals.</brief_summary>
	<brief_title>A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Unresectable Advanced and/or Metastatic Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>adult patients, &gt;=18 years of age; advanced and/or metastatic (stage IIIB/IV) unresectable nonsmall cell lung cancer; no previous systemic chemotherapy, radiation therapy or immunotherapy; Eastern Cooperative Oncology Group (ECOG) &gt;=2. prior systemic antitumor therapy with human epidermal growth factor receptor 1 (HER1/EGFR) inhibitors; active, noncontrolled systemic disease; any other malignancies within 5 years (except for adequately treated cancer in situ of cervix, or basal or squamous cell skin cancer).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>